Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Bellicum Pharmaceuticals (Nasdaq: BLCM) announced that CEO Rick Fair will participate in the H.C. Wainwright 24th Annual Global Investment Conference. A pre-recorded presentation will be available on-demand from September 12, 2022, at 7 a.m. ET for 90 days. The company focuses on controllable cellular immunotherapies for cancers, with its GoCAR-T® product candidates, BPX-601 and BPX-603, designed to enhance CAR-T cell therapy effectiveness. More details can be found on their official website.

HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 24th Annual Global Investment Conference (hybrid). A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET / 4 a.m. PT on September 12, 2022, and will remain accessible for 90 days in the Events and Presentations section of the Bellicum website.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com or follow us on Twitter or LinkedIn.

Investors:
Robert H. Uhl
Managing Director
ICR Westwicke
858-356-5932
Robert.uhl@westwicke.com

FAQ

What is the date for the Bellicum Pharmaceuticals presentation at the H.C. Wainwright Conference?

The Bellicum Pharmaceuticals presentation will be available on-demand starting September 12, 2022.

Who is the CEO of Bellicum Pharmaceuticals participating in the investment conference?

Rick Fair, the President and CEO, will participate in the conference.

What are the key product candidates of Bellicum Pharmaceuticals?

Bellicum's key product candidates include BPX-601 and BPX-603, which are designed to enhance CAR-T cell therapies.

Where can I access the Bellicum Pharmaceuticals presentation after September 12, 2022?

The presentation will be accessible for 90 days in the Events and Presentations section of the Bellicum website.

What is the focus of Bellicum Pharmaceuticals in the biopharmaceutical industry?

Bellicum Pharmaceuticals focuses on developing controllable cellular immunotherapies for cancer treatment.